

*B7*  
NO:7 shown in Figure 15A; SEQ ID NO:15 shown in Figure 15B) --; after  
"Y0313-2", insert -- (SEQ ID NO:8 shown in Figure 15A; SEQ ID NO:16  
*B1D* shown in Figure 15B) --.

On page 13, line 13, delete "WO 98/54331" and insert -- WO  
98/45331 --.

On page 13, line 14, delete "WO 98/54332" and insert -- WO  
98/45332 --.

**IN THE CLAIMS:**

*B1C3*  
Please cancel claims 7 and 28 without prejudice.

1. (Amended) A method of treating a mammal having edema comprising  
administering to said mammal an effective amount of hVEGF antagonist,  
wherein said antagonist comprises an anti-VEGF antibody.

*B1C1*  
22. (Amended) A method of treating a mammal having cerebral edema  
comprising administering to said mammal an effective amount of hVEGF  
antagonist, wherein said antagonist comprises an anti-VEGF antibody.

**REMARKS**

Claims 1-29 are pending and are the subject of the office action.  
As shown in the above amendment, the specification has been amended to  
correct several inadvertent typographical errors relating to certain  
art reference citations. The specification has also been amended to  
recite various SEQ ID NO:s, as discussed below. The claims have also  
been amended in connection with the restriction requirement, as  
discussed below.

In the office action, the Examiner set forth a restriction  
requirement pursuant to 35 USC Section 121. Specifically, the  
Examiner set forth a restriction of six (6) groups of claims, Groups I  
- VI. Applicants hereby elect to prosecute in the instant application  
claims drawn to Group I identified by the Examiner (e.g., claims  
directed to methods of treating edema using antibodies). With respect  
to the election of species requirement set forth by the Examiner,  
Applicants would appreciate clarification of this imposed requirement  
for the record. Applicants do hereby elect to prosecute in the  
instant application claims drawn to monoclonal antibodies. It is